The postmenopausal hormone replacement therapy-related breast cancer risk is decreased in women carrying the CYP2C19*17 variant

Breast Cancer Res Treat. 2012 Jan;131(1):347-50. doi: 10.1007/s10549-011-1827-1. Epub 2011 Oct 26.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aryl Hydrocarbon Hydroxylases / genetics*
  • Breast Neoplasms / genetics*
  • Breast Neoplasms / pathology
  • Cytochrome P-450 CYP2C19
  • Estrogen Replacement Therapy*
  • Female
  • Gonadal Steroid Hormones / blood*
  • Humans
  • Postmenopause
  • Risk

Substances

  • Gonadal Steroid Hormones
  • Aryl Hydrocarbon Hydroxylases
  • CYP2C19 protein, human
  • Cytochrome P-450 CYP2C19